Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resectable NSCLC × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 231 Carcinoma, Non-Small-Cell Lung 223 Prostatic Neoplasms 164 Multiple Myeloma 120 Colorectal Neoplasms 116 Neoplasms 111 Squamous Cell Carcinoma of Head and Neck 106 Leukemia, Myeloid, Acute 105 Neoplasm Metastasis 103 Lung Neoplasms 101 Melanoma 83 Triple Negative Breast Neoplasms 79 Carcinoma, Hepatocellular 78 Ovarian Neoplasms 76 Brain Neoplasms 68 Recurrence 67 Pancreatic Neoplasms 65 Lymphoma 65 Leukemia, Lymphocytic, Chronic, B-Cell 64 Sarcoma 60 Lymphoma, Large B-Cell, Diffuse 58 Carcinoma, Renal Cell 56 Stomach Neoplasms 54 Head and Neck Neoplasms 53 Rectal Neoplasms 51 Precursor Cell Lymphoblastic Leukemia-Lymphoma 50 Glioblastoma 50 Urinary Bladder Neoplasms 49 Endometrial Neoplasms 48 Small Cell Lung Carcinoma 45

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡